The antimalarial potential of targeting Plasmodium PI4Kβ has been demonstrated by the clinicalcandidate MMV390048 (Figure ), which displayed multistage activity invitro and in vivoand reached Phase II clinical trials for the treatment of malaria., Despite good efficacy in the clinical studies, the development of MMV390048 was stopped due to toxicity signals in rodents posinga potential teratogenicity risk. New Plasmodium PI4Kβ inhibitor chemotypes with distinctoff-target profiles are now being explored as alternatives to MMV390048. This evidence concerns the gene PI4KB and malaria.